Erasca Inc (ERAS)vsInsmed Inc (INSM)
ERAS
Erasca Inc
$15.99
+9.00%
HEALTHCARE · Cap: $4.54B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
ERAS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ERAS
Avoid25
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
Trading at 14.0x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ERAS
ERAS has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ERAS
The primary concerns for ERAS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ERAS profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
ERAS carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ERAS generates stronger free cash flow (-22M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Erasca Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Erasca Inc. is a forward-thinking biopharmaceutical company focused on creating targeted therapies for genetically defined cancers to meet significant unmet medical needs in oncology. Utilizing a proprietary drug discovery platform that merges advanced genomics with precision medicine, Erasca concentrates on developing treatments that specifically target key mutations driving cancer progression. With a diverse pipeline of clinical-stage candidates designed to inhibit critical tumor growth pathways, the company aims to enhance the standards of cancer care. Erasca’s commitment to improving patient outcomes is further strengthened by its strategic collaborations and partnerships within the cancer research landscape.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?